InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
61,187.86
(
0.65%
)
Post# of 2804248
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

sgunderbarth

Send PM Follow Ignore
Followers 199
Posts 17210
Boards Moderated 2
Alias Born 02/17/2012

sgunderbarth

Member Level

Re: None

Tuesday, 07/27/2021 7:44:44 AM

Tuesday, July 27, 2021 7:44:44 AM

Post# of 2804248
OCGN “Ocugen initiated with an Outperform at Noble Capital”

Noble Capital analyst Robert LeBoyer initiated coverage of Ocugen with an Outperform rating and $15 price target. The company has in-licensed Covaxin, a whole-virion vaccine for Covid-19 that has advantages over the the current vaccines in use today, LeBoyer tells investors in a research note.

https://m.thefly.com/news-story/3341723/2021-07-26%2010:00:13/search

What we've got here...is failure to communicate. Some men you just can't reach...which is the way he wants it, well, HE GETS IT! And I dont like it anymore than you men.

*Contact your licensed financial advisor before entering the market.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up